Company intelligence / Profile preview
RH Nanopharmaceuticals
United Statesrhnanopharma.com ↗
- Ownership
- Private
- Employees
- ~35
- Development stage
- Other
01
Overview
The company has successfully produced nanoparticles of salsalate to achieve faster onset of action, longer duration of action, and better anti-inflammatory effects. They had a successful Pre-IND Meeting in June 2018 and are in the process of IND submission for their nanosuspension of oral salsalate for immediate relief of pain
- Therapeutic areas
- RheumatologyOphthalmologyEndocrinologyImmunologyOtherNeurology
- Modalities
- Small moleculesnanoparticles
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on RH Nanopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RH Nanopharmaceuticals.